Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools

A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More →

European Parliament Passes Cannabis Resolution, Joins WHO In Supporting Medical Marijuana

Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on Wednesday on a resolution that would help advance medical cannabis in the countries that form the European Union. Read the full story here.
Read More →

$2.7 million awarded for medical marijuana research in Colorado

The state has awarded $2.7 million for research into how medical marijuana could replace opioids to ease chronic spinal pain — and how it might treat irritability in children and adolescents with autism. Read the full story here.
Read More →

DeSantis OKs telehealth for Florida medical marijuana patients

TAMPA, Fla. (WFLA) — Florida Gov. Ron DeSantis signed a bill allowing the state’s 828,000 medical marijuana patients to use telehealth to visit their doctors. On Monday, DeSantis signed HB-387, titled “Medical Use of Marijuana,” which allows patients renewing their medical marijuana recommendation to meet with their doctors online. Currently, patients must visit their doctor in person…
Read More →

Research shows cannabis can lower opioid dosage, but studies are preliminary

Larson cited one statistic to justify his bill: “Studies have shown up to 75% reduction in opioid dosage for medical cannabis users” The intersection of medical cannabis and opioid use as treatments for chronic pain is an emerging field of research as more states loosen regulations on medical and recreational use of marijuana. But does…
Read More →

Alternative Mississippi medical marijuana program barely wins approval from Senate

JACKSON • Legislation that would create a new medical marijuana program in Mississippi if the voter-approved Initiative 65 is overturned in court cleared the state Senate on the second try last week early on Friday morning. Senate Bill 2765, the Mississippi Medical Cannabis Act, failed by a single vote Thursday evening. But six hours later, after…
Read More →

Leave a Comment

You must be logged in to post a comment.